Why is Hydroxyurea First Line Therapy in the US for Essential Thrombocythemia?

Earn CME for related activities: https://hmpeducation.com/

As recent discoveries have the potential to change the paradigm of how MPN and MDS are diagnosed and treated, it is imperative that healthcare professionals who treat these diseases are provided expert review of the most pertinent clinical data pertaining to prognosis, diagnosis, therapy and disease management and guidance for their optimal integration into everyday clinical practice.

The US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes 2015 provides a platform to resolve many of the clinical challenges for diagnosis and treatment through presentations and interactive discussions of the latest clinical and research findings pertaining to MPN and MDS. Topics that will be deliberated include updates in therapeutic interventions of MDS, polycythemia vera, essential thrombocytopenia and myelofibrosis.

In this presentation, Dr. Olatoyois Odenike discusses why hydroxyurea is the first line therapy option in the United States for essential thromobcythemia instead of anagrelide or interferon.